Ilyang Pharm (KO:007570) — Market Cap & Net Worth
Market Cap & Net Worth: Ilyang Pharm (007570)
Ilyang Pharm (KO:007570) has a market capitalization of $96.09 Million (₩141.79 Billion) as of September 17, 2026. Listed on the KO stock exchange, this Korea-based company holds position #19412 globally and #968 in its home market, demonstrating a -5.04% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ilyang Pharm's stock price ₩7910.00 by its total outstanding shares 17924965 (17.92 Million). Also see 007570 asset base for a full breakdown of the balance sheet.
Ilyang Pharm Market Cap History: 2015 to 2026
Ilyang Pharm's market capitalization history from 2015 to 2026. Data shows change from $580.75 Million to $96.09 Million (-15.12% CAGR). Also see Ilyang Pharm (007570) cash flow conversion for how efficiently the company converts equity into cash flow.
Ilyang Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ilyang Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Ilyang Pharm stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Ilyang Pharm's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
Ilyang Pharm's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $580.75 Million | $239.26 Billion | $4.41 Billion | 0.00x | 0.13x |
| 2016 | $494.84 Million | $261.61 Billion | $5.91 Billion | 0.00x | 0.08x |
| 2017 | $458.01 Million | $269.81 Billion | $6.26 Billion | 0.00x | 0.07x |
| 2018 | $326.73 Million | $300.04 Billion | -$4.89 Billion | 0.00x | N/A |
| 2019 | $269.39 Million | $324.57 Billion | $9.98 Billion | 0.00x | 0.03x |
| 2020 | $787.61 Million | $343.33 Billion | $10.88 Billion | 0.00x | 0.07x |
| 2021 | $338.18 Million | $371.35 Billion | $14.38 Billion | 0.00x | 0.02x |
| 2022 | $235.05 Million | $383.81 Billion | $19.24 Billion | 0.00x | 0.01x |
| 2023 | $190.11 Million | $266.67 Billion | -$2.41 Billion | 0.00x | N/A |
| 2024 | $138.60 Million | $268.86 Billion | $10.26 Billion | 0.00x | 0.01x |
Competitor Companies of 007570 by Market Capitalization
Companies near Ilyang Pharm in the global market cap rankings as of September 17, 2026. Review Ilyang Pharm tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Ilyang Pharm by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Ilyang Pharm Historical Marketcap From 2015 to 2026
Between 2015 and today, Ilyang Pharm's market cap moved from $580.75 Million to $ 96.09 Million, with a yearly change of -15.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩96.09 Million | -39.39% |
| 2025 | ₩158.52 Million | +14.37% |
| 2024 | ₩138.60 Million | -27.09% |
| 2023 | ₩190.11 Million | -19.12% |
| 2022 | ₩235.05 Million | -30.49% |
| 2021 | ₩338.18 Million | -57.06% |
| 2020 | ₩787.61 Million | +192.37% |
| 2019 | ₩269.39 Million | -17.55% |
| 2018 | ₩326.73 Million | -28.66% |
| 2017 | ₩458.01 Million | -7.44% |
| 2016 | ₩494.84 Million | -14.79% |
| 2015 | ₩580.75 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Ilyang Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $96.09 Million USD |
| MoneyControl | $96.09 Million USD |
| MarketWatch | $96.09 Million USD |
| marketcap.company | $96.09 Million USD |
| Reuters | $96.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ilyang Pharm
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, anti… Read more